

## PRESS RELEASE

03.05.2023

# IIF Digital Capital Markets Conference: Biotechnology ensures healthy returns

**Millions of people affected by cancer, Alzheimer's or Parkinson's are fighting the battle primarily on their own. Innovative biotechs are preparing to cure these diseases and alleviate suffering. The 7th edition of the International Investment Forum (IIF) digital investor conference will feature three promising biotechs: Morphosys, BioNxt and Defence Therapeutics.**

In April, R21/Matrix-M, a malaria vaccine with a protective effect of more than 75%, was approved for the first time. The vaccine has received national approval from the authorities in Ghana and is primarily intended to protect children between 5 and 36 months, who are the most common victims of malaria. Developed at the University of Oxford after about 80 years of malaria research, the vaccine achieves a protective efficacy that is suitable for significantly reducing the impact of the pathogen. R21/Matrix-M is currently in Phase III clinical trials but already has a production capacity of 200 million doses per year. The World Health Organisation (WHO) is also considering approval.

"The success of R21/Matrix-M demonstrates the need for continuous research and the use of innovative assistive technologies to achieve ambitious goals. As experts comment, the high protective efficacy of the new vaccine is also based on innovations in simultaneously administered drug enhancers," says Manuel Hölzle, CEO of research house GBC AG and one of the two co-organizers of the IIF. "At the seventh edition of our digital investor conference, Morphosys AG, Defence Therapeutics Inc. and BioNxt Solutions Inc. represent three companies that want to score points on the market with their innovative solutions and are also aiming high," says Hölzle.

Morphosys from Planegg near Munich has a pipeline for the treatment of cancer, rheumatism and Alzheimer's disease and is considered a specialist in therapeutic antibodies. The Company operates primarily in the US, where it cooperates with Incyte. In addition to product sales, Morphosys also generates revenues from licences and milestone payments. The Canadian-German biotech BioNxt is also facing noteworthy sales. The Company covers the business areas of innovative dosage forms, diagnostics and psychedelic substances. In the first two business areas, partnerships with pharmaceutical companies already exist. Only recently, BioNxt created production capacities at its German subsidiary Vektor Pharma TF GmbH and wants to land more customers as a contract manufacturer for pharmaceutical companies.

Defence Therapeutics has positioned itself around the future technology of mRNA. With its patented Accum™ technology, the Canadian biotech company has a substance that is intended to make it easier for all biological agents to overcome hurdles within target cells. The technology is considered to be very flexible and is the main component of vaccines and chemotherapeutics that Defence Therapeutics plans to take into clinical trials in the coming months. Comparative studies are currently underway to demonstrate the positive effects of Accum™ in mRNA vaccines as well. In the field of

nuclear medicine, Defence Therapeutics recently entered into a collaboration with the French state-owned Orano Group.

"The three biotech companies participating in the IIF on May 10 2023, can offer investors and interested parties valuable insights into a promising industry. The growing cost pressure in the healthcare sector, but also demographic factors, make innovative solutions necessary. Morphosys, BioNxt and Defence Therapeutics show that medical progress can succeed in different ways. Often, innovative dosage forms or other assistive technologies are needed to successfully use promising active substances in the fight against diseases," says Mario Hose, Managing Director of Apaton Finance GmbH and co-organizer of the IIF.

In addition to the biotech companies mentioned above, companies from the hydrogen, battery technology, industrial and mining sectors will also be presenting in concise 30-minute slots during the May edition of the IIF.

The 7th IIF will take place on May 10, 2023. [Participation is free](#) via Zoom and registration is possible at [www.ii-forum.com](http://www.ii-forum.com).

Program   IIF - International Investment Forum   # 7   May 10, 2023			
Company Name	ISIN	Speaker	Time
FACC AG	(ISIN AT00000FACC2)	Ales Starek, CFO	10.00 am CEST*
Renforth Ressources Inc.	(ISIN CA75971C2094)	Nicole Brewster, President & CEO	10.30 am CEST*
Samara Asset Group – formerly Cryptology Asset Group PLC	(ISIN MT0001770107)	Patrick Lowry, CEO	11.00 am CEST*
First Tin plc	ISIN: GB00BNR45554	Thomas Buenger, CEO	11.30 am CEST*
Landi Renzo S.p.A.	(ISIN IT0004210289)	Cristiano Musi, CEO	12.00 pm CEST*
Morphosys AG	(ISIN DE0006632003)	Dr. Julia Neugebauer, Vice President & Head of IR	12:30 pm CEST*
INDUS Holding AG	(ISIN DE0006200108)	Dafne Sanac, Head of IR	01.00 pm CEST*
PSI Software AG	(ISIN DE000A021JH9)	Karsten Pierschke, Head of IR	01.30 pm CEST*
First Phosphate Corp.	(ISIN CA33611D1033)	John Passalacqua, CEO and Director	02.00 pm CEST*
Defense Metals Corp.	(ISIN CA2446331035)	Dr. Luisa Moreno, President & Director	02.30 pm CEST*
First Hydrogen Corp.	(ISIN CA32057N1042)	Robert Campbell, CEO First Hydrogen Energy	03.00 pm CEST*
Defence Therapeutics Inc.	(ISIN CA24463V1013)	Dr. Moutih Rafei, VP R&D, Director	03.30 pm CEST*
Almonty Industries Inc.	(ISIN CA0203981034)	Lewis Black, CEO	04.00 pm CEST*
Power Nickel Inc.	(ISIN CA7393011092)	Terry Lynch, CEO	04.30 pm CEST*
dynaCERT Inc.	(ISIN CA26780A1084)	Jim Payne, CEO	05.00 pm CEST*
Altech Advanced Materials AG	(ISIN DE000A31C3Y4)	Uwe Ahrens, CEO	05.30 pm CEST*
Saturn Oil & Gas Inc.	(ISIN CA80412L8832)	Kevin Smith, VP Corporate Development	06.00 pm CEST*
Star Navigation Systems Group Ltd.	(ISIN CA8551571034)	Anoop Brar, Interim-CEO	06.30 pm CEST*
BioNxt Solutions Inc.	(ISIN CA0909741062)	Hugh Rogers, CEO & Director	07.00 pm CEST*
Desert Gold Ventures Inc.	(ISIN CA25039N4084)	Jared Scharf, CEO	07.30 pm CEST*

###

#### **About IIF – International Investment Forum**

The 7th IIF – International Investment Forum - will take place on May 10, 2023. Companies and their board members or top managers will present and answer question from investors via Zoom. The event will start at 9:55 CEST (Central European Summer Time) and end at 20:00 CEST. The event is organized from Germany as a cooperation project between Apaton Finance GmbH and GBC AG.

For further information: [www.ii-forum.com](http://www.ii-forum.com)

#### **About Apaton Finance GmbH (Co-Organizer)**

Apaton focuses primarily on growth companies and helps to build investor relationships. Partners are located all over the world. When a company is in a transition phase and enters a new market or a growth phase, Apaton becomes active. Apaton's experts create investable visibility in new regions and markets.

Press Contact:

Mario Hose

+49 511 67 68 731

[press@apaton.com](mailto:press@apaton.com)

#### **About GBC AG (Co-Organizer)**

GBC AG has been organizing capital market conferences since 2001. Around two-thirds of all German issuers from the small & mid cap sectors have already used GBC Conferences in the 20 years of conference history to address the capital market directly. Generally, the GBC conference series aims primarily at asset managers, fund managers, family offices, analysts, and financial journalists.

Press Contact:

Marita Conzelmann

+49 821 241133-49

[konferenz@gbc-ag.de](mailto:konferenz@gbc-ag.de)